GlassScriptPhysician profile
Henry C Echiverri
NPI 1356347264
$50,470.31
in general payments reported to CMS, 2019-2025
31 companies · $2,234 in 2025
The $2,234 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $4,820 · 2021: $19K · 2022: $1,270 · 2023: $1,543 · 2024: $1,821 · 2025: $2,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,497 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,497.40 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $34,897.08 | 2019-2025 | |
| Amgen INC. | $7,672.35 | 2019-2025 | Uplizna |
| Abbvie INC. | $1,623.38 | 2021-2025 | Qulipta, Ubrelvy |
| Biogen, INC. | $1,565.19 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Horizon Therapeutics Plc | $988.63 | 2021-2023 | Uplizna |
| Celgene Corporation | $851.26 | 2021-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $576.29 | 2019-2025 | |
| Eisai INC. | $364.25 | 2024-2025 | |
| Genentech USA, INC. | $283.14 | 2020-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $235.46 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $194.41 | 2021-2022 | |
| Emd Serono, INC. | $183.80 | 2019-2024 | Mavenclad |
| Banner Life Sciences, LLC | $122.91 | 2024 | |
| Sanofi-Aventis U.S. LLC | $121.91 | 2019-2021 | |
| Boston Scientific Corporation | $121.87 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $103.49 | 2025 | Gomekli |
| Alexion Pharmaceuticals, INC. | $100.00 | 2024 | Ultomiris |
| Axsome Therapeutics, INC. | $79.07 | 2025 | Symbravo |
| Alnylam Pharmaceuticals INC. | $45.10 | 2025 | Amvuttra |
| Allergan, INC. | $43.31 | 2020 | |
| Mallinckrodt Enterprises LLC | $41.32 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $35.80 | 2019-2020 | |
| Argenx US, INC. | $34.84 | 2022-2025 | Vyvgart Hytrulo |
| Livanova USA, INC. | $30.80 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $28.62 | 2021 | |
| Corium, LLC | $28.26 | 2023 | Adlarity |
| Lilly USA, LLC | $27.50 | 2025 | Amyvid, Kisunla |
| Cala Health, INC. | $23.85 | 2023 | Cala Trio |
| Pfizer INC. | $20.17 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $14.99 | 2021 | |
| Csl Behring | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Echiverri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.